Given only some patients benefit from MEK inhibitors in the treatment of KRAS-mutant pancreatic cancers, we were encouraged to investigate whether different KRAS-mutant human pancreatic cancer cell lines respond differently to MEK inhibition. This evidence concerns the gene MAP2K7 and pancreatic neoplasm.